TB Vaccines for the World

23-25 May 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size


One in every three people on earth is believed to be infected with Mycobacterium tuberculosis, leading to seven to eight million cases of active tuberculosis (TB) per year and approximately three million deaths annually. This epidemic, like those of most infectious diseases, creates scientific challenges and opportunities as it raises the demand for public health solutions. The currently available weapons for fighting TB are inadequate. The ultimate goal of biomedical TB research is to lessen the public health burden of this disease by developing improved diagnostic, therapeutic, and intervention strategies. Achieving this goal requires a base of knowledge about the biology of M. tuberculosis and related mycobacteria, their interactions with human and animal hosts, and the nature of an effective host-protective immune response. TB researchers are applying this accumulating base of knowledge to developing rapid, easy-to-use diagnostic assays appropriate for low- as well as high-income countries, improving the current complicated therapeutic regimen, identifying potential new drugs to combat multidrug-resistant TB, and creating more effective vaccines.

TBV 2012, the follow-up to the previous successful TBV meetings in 2003, 2006 and 2008, will focus attention on ‘Vaccine Issues’ in relation to TB worldwide. TB vaccines is a developing area of activity and TBV 2012 will once again allow researchers to come together to discuss the latest findings and trends associated with the research and development of TB vaccines – science, policy, strategy, delivery and economics.

Scientific Advisory Panel

Patrick Brennan (Colorado State University, USA)
Steve Reed (IDRI, Seattle, USA)
Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)
Tom Ottenhoff (Leiden University, The Netherlands)
Alexander von Gabain (Intercell AG, Vienna, Austria)
Ian Orme (Colorado State University, USA)
Andrew Vernon (CDC, Atlanta, Georgia, USA)
Joe Cohen (GSK Biologicals, Rixensart, Belgium)
Sheldon Morris (CBER/FDA, Rockville, Maryland, USA)
Leander Grode (Vakzine Projekt Management GmbH, Hannover, Germany)
Willem Hanekom (University of Cape Town, South Africa)
Michael Iademarco (CDC, Atlanta, Georgia, USA)
Jeffrey Ulmer (Novartis Vaccines, Cambridge, Massachusetts, USA)
Helen McShane (University of Oxford, UK)

‘New Vaccine Strategies’

  • TBV Vaccines Overview
  • BCG – “Myths and Realities”
  • The Immune Response
  • ‘Would the Real TB Strain Please Stand Up’
  • Non-Living Vaccines and Adjuvants
  • Live Attenuated Vaccines
  • Biomarkers/Metabolomics
  • The Ghost in the Machine: Regulatory T Cell Responses
  • Clinical Issues
  • New Models/Testing Strategies

TBV 2012 Delegates

Login details will be supplied after you have registered for the event.

TBV 2012 Sponsors

  • Intercell Smart Vaccines
  • Centers for Disease Control and Prevention
  • Vakzine Project Management
  • Infectious Disease Research Institute

TBV 2012 Downloads

TBV 2012 Leaflet

TBV 2012 Mailing List

E-mail Address
What is 1+4-2?